(Corrects headline to “Convelo Therapeutics Enters Worldwide Collaboration with Genentech” from “Convelo Therapeutics to Acquire Genentech”. Also corrects source to “Convelo Therapeutics” from “Roche Holding AG”)
July 16 (Reuters) - CONVELO THERAPEUTICS:
* CONVELO THERAPEUTICS ENTERS INTO COLLABORATION AND OPTION TO ACQUIRE AGREEMENT WITH GENENTECH TO DISCOVER NOVEL REMYELINATING THERAPIES
* CONVELO THERAPEUTICS - CONVELO WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND RESEARCH SUPPORT FROM GENENTECH.
* CONVELO THERAPEUTICS - CONVELO AND GENENTECH WILL COLLABORATE TO DISCOVER NOVEL REMYELINATION THERAPIES FOR MS AND OTHER MYELIN DISORDERS
* CONVELO - GENENTECH RETAINS EXCLUSIVE OPTION TO ACQUIRE OUTSTANDING STOCK OF CONVELO FOR ADDITIONAL UNDISCLOSED PAYMENT & DOWNSTREAM MILESTONES. Source text for Eikon: Further company coverage: